These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27873082)

  • 1. I Can See Clearly Now: Using Active Visualisation to Improve Adherence to ART and PrEP.
    Jones AS; Petrie KJ
    AIDS Behav; 2017 Feb; 21(2):335-340. PubMed ID: 27873082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers.
    Bardon AR; Simoni JM; Layman LM; Stekler JD; Drain PK
    AIDS Res Ther; 2020 Aug; 17(1):50. PubMed ID: 32762713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing ART adherence: update for HIV treatment and prevention.
    Robbins RN; Spector AY; Mellins CA; Remien RH
    Curr HIV/AIDS Rep; 2014 Dec; 11(4):423-33. PubMed ID: 25304006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Use of a Brief, Active Visualisation Intervention to Improve Adherence to Antiretroviral Therapy in Non-adherent Patients in South Africa.
    Jones ASK; Coetzee B; Kagee A; Fernandez J; Cleveland E; Thomas M; Petrie KJ
    AIDS Behav; 2019 Aug; 23(8):2121-2129. PubMed ID: 30259346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication adherence among men who have sex with men at risk for HIV infection in the United States: implications for pre-exposure prophylaxis implementation.
    Liu AY; Hessol NA; Vittinghoff E; Amico KR; Kroboth E; Fuchs J; Irvin R; Sineath RC; Sanchez T; Sullivan PS; Buchbinder SP
    AIDS Patient Care STDS; 2014 Dec; 28(12):622-7. PubMed ID: 25396706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Point-of-care and Near Real-time Testing for Antiretroviral Adherence Monitoring to HIV Treatment and Prevention.
    Drain PK; Bardon AR; Simoni JM; Cressey TR; Anderson P; Sevenler D; Olanrewaju AO; Gandhi M; Celum C
    Curr HIV/AIDS Rep; 2020 Oct; 17(5):487-498. PubMed ID: 32627120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of medication therapy management in preexposure prophylaxis therapy for HIV prevention.
    Ferrell KW; Woodard LM; Woodard TJ
    J Pharm Pract; 2015 Feb; 28(1):10-2. PubMed ID: 25500557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Injectable Antiretroviral Drugs: Back to the Future.
    Berruti M; Riccardi N; Canetti D; Lo Caputo S; Taramasso L; Di Biagio A
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33540877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maximizing the benefits of ART and PrEP in resource-limited settings.
    Akudibillah G; Pandey A; Medlock J
    Epidemiol Infect; 2017 Apr; 145(5):942-956. PubMed ID: 28031062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project.
    Eakle R; Gomez GB; Naicker N; Bothma R; Mbogua J; Cabrera Escobar MA; Saayman E; Moorhouse M; Venter WDF; Rees H;
    PLoS Med; 2017 Nov; 14(11):e1002444. PubMed ID: 29161256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scaling-up PrEP Delivery in Sub-Saharan Africa: What Can We Learn from the Scale-up of ART?
    O'Malley G; Barnabee G; Mugwanya K
    Curr HIV/AIDS Rep; 2019 Apr; 16(2):141-150. PubMed ID: 30796608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Depressive Symptoms with Lapses in Antiretroviral Medication Adherence Among People Living with HIV: A Test of an Indirect Pathway.
    Babowitch JD; Sheinfil AZ; Woolf-King SE; Vanable PA; Sweeney SM
    AIDS Behav; 2018 Oct; 22(10):3166-3174. PubMed ID: 29572762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infection with antiretroviral-susceptible HIV in an individual adherent to pre-exposure prophylaxis: strategies for treatment initiation.
    Hughes JM; Tan DH; Anderson P; Bodhinayake J; MacPherson PA
    Int J STD AIDS; 2021 May; 32(6):578-581. PubMed ID: 33663292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence Measurements in HIV: New Advancements in Pharmacologic Methods and Real-Time Monitoring.
    Castillo-Mancilla JR; Haberer JE
    Curr HIV/AIDS Rep; 2018 Feb; 15(1):49-59. PubMed ID: 29380227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
    Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
    AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across Six Cities in the Women's Interagency HIV Study: Intersections with Current and Past Injectable Medication and Substance Use.
    Philbin MM; Parish C; Bergen S; Kerrigan D; Kinnard EN; Reed SE; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Fischl M; Alcaide ML; Metsch LR
    AIDS Patient Care STDS; 2021 Jan; 35(1):23-30. PubMed ID: 33400587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice.
    Haberer JE
    Curr Opin HIV AIDS; 2016 Jan; 11(1):10-7. PubMed ID: 26633638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invited commentary: every good randomization deserves observation.
    Westreich D; Edwards JK
    Am J Epidemiol; 2015 Nov; 182(10):857-60. PubMed ID: 26487342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of oral HIV pre-exposure prophylaxis and early antiretroviral therapy in the presence of drug resistance among men who have sex with men in San Francisco.
    Shen M; Xiao Y; Rong L; Meyers LA; Bellan SE
    BMC Med; 2018 Apr; 16(1):58. PubMed ID: 29688862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using Behavioral Economics to Support PrEP Adherence for HIV Prevention.
    Roy Paladhi U; Katz DA; Farquhar C; Thirumurthy H
    Curr HIV/AIDS Rep; 2022 Oct; 19(5):409-414. PubMed ID: 36044119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.